![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 54, Issue 6, 1064-1072, December 1998
Department of Pharmacology and Toxicology, Medical College of
Georgia, Augusta, Georgia 30912-2300
The CB1 cannabinoid receptor antagonist SR 141716A abolished the
inhibition of Ca2+ currents by the agonist WIN 55,212-2.
However, SR 141716A alone increased Ca2+ currents, with an
EC50 of 32 nM, in neurons that had been
microinjected with CB1 cRNA. For an antagonist to elicit an effect,
some receptors must be tonically active. Evidence for tonically active
CB1 receptors was seen as enhanced tonic inhibition of Ca2+
currents. Preincubation with anandamide failed to enhance the effect of
SR 141716A, indicating that anandamide did not cause receptor activity.
Under Ca2+-free conditions designed to block the
Ca2+-dependent formation of anandamide and
sn-2-arachidonylglycerol, SR 141716A again increased the
Ca2+ current. The Ca2+ current was tonically
inhibited in neurons expressing the mutant K192A receptor, which has no
affinity for anandamide, demonstrating that this receptor is also
tonically active. SR 141716A had no effect on the Ca2+
current in these neurons, but SR 141716A could still antagonize the
effect of WIN 55,212-2. Thus, the K192 site is critical for the
inverse agonist activity of SR 141716A. SR 141716A appeared to become a
neutral antagonist at the K192A mutant receptor. Native cannabinoid
receptors were studied in male rat major pelvic ganglion neurons, where
it was found that WIN 55,212-2 inhibited and SR 141716A increased
Ca2+ currents. Taken together, our results demonstrate that
a population of native and cloned CB1 cannabinoid receptors can exist
in a tonically active state that can be reversed by SR 141716A, which acts as an inverse agonist.
This article has been cited by other articles:
|
|
 |
|
  M. J. S. Chee, K. Morl, D. Lindner, N. Merten, G. W. Zamponi, P. E. Light, A. G. Beck-Sickinger, and W. F. Colmers The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor J. Biol. Chem., November 28, 2008; 283(48): 33337 - 33346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fioravanti, M. De Felice, C. L. Stucky, K. A. Medler, M.-C. Luo, L. R. Gardell, M. Ibrahim, T. P. Malan Jr, H. I. Yamamura, M. H. Ossipov, et al. Constitutive Activity at the Cannabinoid CB1 Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists J. Neurosci., November 5, 2008; 28(45): 11593 - 11602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Niehaus, Y. Liu, K. T. Wallis, M. Egertova, S. G. Bhartur, S. Mukhopadhyay, S. Shi, H. He, D. E. Selley, A. C. Howlett, et al. CB1 Cannabinoid Receptor Activity Is Modulated by the Cannabinoid Receptor Interacting Protein CRIP 1a Mol. Pharmacol., December 1, 2007; 72(6): 1557 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Anavi-Goffer, D. Fleischer, D. P. Hurst, D. L. Lynch, J. Barnett-Norris, S. Shi, D. L. Lewis, S. Mukhopadhyay, A. C. Howlett, P. H. Reggio, et al. Helix 8 Leu in the CB1 Cannabinoid Receptor Contributes to Selective Signal Transduction Mechanisms J. Biol. Chem., August 24, 2007; 282(34): 25100 - 25113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Turu, A. Simon, P. Gyombolai, L. Szidonya, G. Bagdy, Z. Lenkei, and L. Hunyady The Role of Diacylglycerol Lipase in Constitutive and Angiotensin AT1 Receptor-stimulated Cannabinoid CB1 Receptor Activity J. Biol. Chem., March 16, 2007; 282(11): 7753 - 7757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chen, A. Neu, A. L. Howard, C. Foldy, J. Echegoyen, L. Hilgenberg, M. Smith, K. Mackie, and I. Soltesz Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures J. Neurosci., January 3, 2007; 27(1): 46 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Neu, C. Foldy, and I. Soltesz Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus J. Physiol., January 1, 2007; 578(1): 233 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Leterrier, J. Laine, M. Darmon, H. Boudin, J. Rossier, and Z. Lenkei Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J. Neurosci., March 22, 2006; 26(12): 3141 - 3153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mukhopadhyay and A. C. Howlett Chemically Distinct Ligands Promote Differential CB1 Cannabinoid Receptor-Gi Protein Interactions Mol. Pharmacol., June 1, 2005; 67(6): 2016 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. McAllister, D. P. Hurst, J. Barnett-Norris, D. Lynch, P. H. Reggio, and M. E. Abood Structural Mimicry in Class A G Protein-coupled Receptor Rotamer Toggle Switches: THE IMPORTANCE OF THE F3.36(201)/W6.48(357) INTERACTION IN CANNABINOID CB1 RECEPTOR ACTIVATION J. Biol. Chem., November 12, 2004; 279(46): 48024 - 48037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Leterrier, D. Bonnard, D. Carrel, J. Rossier, and Z. Lenkei Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor J. Biol. Chem., August 20, 2004; 279(34): 36013 - 36021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Spruce, L. A. Campbell, N. McTavish, M. A. Cooper, M. V. L. Appleyard, M. O'Neill, J. Howie, J. Samson, S. Watt, K. Murray, et al. Small Molecule Antagonists of the {sigma}-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo Cancer Res., July 15, 2004; 64(14): 4875 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Akerman, H. Kaube, and P. J. Goadsby Anandamide Is Able to Inhibit Trigeminal Neurons Using an in Vivo Model of Trigeminovascular-Mediated Nociception J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 56 - 63. [Abstract] [Full Text]
|
|
|
|
|
|
J. Guo and S. R. Ikeda Endocannabinoids Modulate N-Type Calcium Channels and G-Protein-Coupled Inwardly Rectifying Potassium Channels via CB1 Cannabinoid Receptors Heterologously Expressed in Mammalian Neurons Mol. Pharmacol., March 1, 2004; 65(3): 665 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Solinas, L. V. Panlilio, K. Antoniou, L. A. Pappas, and S. R. Goldberg The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in Rats J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, M. Isokawa, C. Ledent, and B. E. Alger Activation of Muscarinic Acetylcholine Receptors Enhances the Release of Endogenous Cannabinoids in the Hippocampus J. Neurosci., December 1, 2002; 22(23): 10182 - 10191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Hurst, D. L. Lynch, J. Barnett-Norris, S. M. Hyatt, H. H. Seltzman, M. Zhong, Z.-H. Song, J. Nie, D. Lewis, and P. H. Reggio N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) Interaction with LYS 3.28(192) Is Crucial for Its Inverse Agonism at the Cannabinoid CB1 Receptor Mol. Pharmacol., December 1, 2002; 62(6): 1274 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Laine, K. Jarvinen, D. W. Pate, A. Urtti, and T. Jarvinen Effect of the Enzyme Inhibitor, Phenylmethylsulfonyl Fluoride, on the IOP Profiles of Topical Anandamides Invest. Ophthalmol. Vis. Sci., February 1, 2002; 43(2): 393 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nie and D. L. Lewis Structural Domains of the CB1 Cannabinoid Receptor That Contribute to Constitutive Activity and G-Protein Sequestration J. Neurosci., November 15, 2001; 21(22): 8758 - 8764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Morisset and L. Urban Cannabinoid-Induced Presynaptic Inhibition of Glutamatergic EPSCs in Substantia Gelatinosa Neurons of the Rat Spinal Cord J Neurophysiol, July 1, 2001; 86(1): 40 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Coutts, S. Anavi-Goffer, R. A. Ross, D. J. MacEwan, K. Mackie, R. G. Pertwee, and A. J. Irving Agonist-Induced Internalization and Trafficking of Cannabinoid CB1 Receptors in Hippocampal Neurons J. Neurosci., April 1, 2001; 21(7): 2425 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Auclair, S. Otani, P. Soubrie, and F. Crepel Cannabinoids Modulate Synaptic Strength and Plasticity at Glutamatergic Synapses of Rat Prefrontal Cortex Pyramidal Neurons J Neurophysiol, June 1, 2000; 83(6): 3287 - 3293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Glass and J. K. Northup Agonist Selective Regulation of G Proteins by Cannabinoid CB1 and CB2 Receptors Mol. Pharmacol., December 1, 1999; 56(6): 1362 - 1369. [Abstract] [Full Text]
|
|
|
|
|
|
S. D. McAllister, G. Griffin, L. S. Satin, and M. E. Abood Cannabinoid Receptors Can Activate and Inhibit G Protein-Coupled Inwardly Rectifying Potassium Channels in a Xenopus Oocyte Expression System J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 618 - 626. [Abstract] [Full Text]
|
|
|
|
|
|
C. Vasquez and D. L. Lewis The CB1 Cannabinoid Receptor Can Sequester G-Proteins, Making Them Unavailable to Couple to Other Receptors J. Neurosci., November 1, 1999; 19(21): 9271 - 9280. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
